Two popular ideas from the discovery sweep, rejected for different reasons.
Covered calls on the core
Selling calls against index holdings “for income” has decades-long real benchmarks, so no backtest was
needed: the CBOE buy-write index earned 8.5%/yr versus 11.1% for the S&P itself, and the best-known
covered-call ETF earned 6.4%/yr versus 16.5% for the index it writes on. The premium is real; the upside you
sell is worth more.
It is worse for us than for most: our stock sleeve’s returns are heavily right-skewed. In our own
data, capping each pick’s monthly return at +15% cuts the average monthly contribution by more than half
— the top 5% of pick-months carry roughly three-quarters of the sleeve’s total return. A covered call is
precisely a cap on the right tail. Selling the right tail sells the edge.
13F cloning
Copying famous funds’ quarterly filings fails on timeliness: positions arrive up to 45 days stale, external
evidence on clone portfolios is mixed, and our own insider-activity research covers the “smart money
footprint” idea with fresher data. Not built.
Verdict: both rejected. Income that costs more than it pays isn’t income.